An independent peptide reference — no sellers, every claim sourced

GLOW

Also known as GLOW blend, Glow Protocol, GHK-Cu / BPC-157 / TB-500 blend

Seller-invented mixture of GHK-Cu, BPC-157 and TB-500; no study has ever been published on it as a blend.

preclinical Blends & stacks research chemical

At a glance

Category
Blends & stacks
Status
research chemical
Route
subcutaneous, in practice into abdominal subcutaneous fat
Half-life
Not established for the mixture, and there is no reason to expect a single figure. The three components differ by orders of magnitude in size and stability, and none of them has published human pharmacokinetics 2. Whatever is injected as one dose does not leave the body as one dose.
Onset
unknown; user protocols speak of weeks
Molecular weight
Not applicable to a mixture. The individual masses are approximately 340 g/mol for GHK (approximately 404 g/mol as the copper complex), 1419.5 g/mol for BPC-157 and approximately 889 g/mol for the TB-500 fragment.
Sequence
Not applicable: a physical mixture of three separate peptides, co-lyophilised in one vial. GHK (Gly-His-Lys) complexed with copper(II), BPC-157 (GEPPPGKPADDAGLV) and the acetylated heptapeptide Ac-LKKTETQ.

Not a medicine and not an approved product anywhere. 'GLOW' is a marketing name coined by peptide vendors, not a pharmacological designation, so there is no standard behind it. In the US the route through a compounding pharmacy is closed: in September 2023 the FDA placed BPC-157 in category 2 of the interim 503A bulks list ('may present significant safety risks'), and 'Thymosin Beta-4, Fragment (LKKTETQ)' was listed by name in the same category. A mixture cannot be lawfully compounded from substances that may not be compounded individually. What is sold is grey-market material labelled 'for research use only'.

Doping status: Prohibited: BPC-157 falls under S0 and TB-500 under S2. The blend as a whole is therefore prohibited for athletes under the WADA code.

Checked against the WADA 2026 Prohibited List. For a specific product and country, Global DRO is the lookup athletes are expected to use — the List names substances, not brand names.

What is in it

Mechanism of action

GLOW has no mechanism of its own. It is three compounds in one vial, each with its own proposed pathway, and the marketing rationale is that skin (GHK-Cu), soft tissue (BPC-157) and cell migration (TB-500) are addressed simultaneously. That is a commercial argument about coverage, not a pharmacological argument about synergy. Nothing in the published literature establishes that these three act on a shared pathway, potentiate one another, or should be given in a 5:1:1 mass ratio.

GHK-Cu is a copper-carrying tripeptide that modulates gene expression associated with collagen synthesis, wound repair and antioxidant defence. Its human evidence base is topical: small cosmetic studies of creams and serums. There is no published human trial of injected GHK-Cu for any indication, and the leap from nanomolar concentrations in cell culture to milligrams injected daily has never been validated.

BPC-157 is described as rebalancing the nitric oxide system and as acting through a VEGFR2-Akt-eNOS route in fibroblasts and tenocytes. Almost all of that work comes from a single research group in rodents, and there is not one published randomised human trial.

TB-500 is residues 17-23 of thymosin beta-4, the actin-binding motif. The clinically studied molecule is the full 43-residue protein, not this fragment; the fragment itself has no published human pharmacokinetics at all and cannot generate the antifibrotic N-terminal fragment Ac-SDKP.

The interaction question is entirely open, and it runs in both directions. Two of the three components are described as pro-angiogenic and the third carries copper, which is itself a cofactor in angiogenesis. Whether that stacks, cancels out or does something else in a human being has never been measured. There is also a straightforward chemistry problem specific to this mixture: GHK-Cu is a copper(II) chelate, and copper(II) in solution catalyses oxidation of peptide side chains. Whether co-lyophilising and co-dissolving BPC-157 and TB-500 alongside a copper complex affects their stability in the vial has, as far as can be established, never been tested and published by anyone.

What the research shows

There is no research on GLOW. A search of PubMed for the blend as a blend returns nothing, and no registered trial of the mixture could be found. This is not a gap that the component literature fills in: the evidence for a mixture is not the sum of the evidence for its parts. Combining three compounds that are individually poorly studied does not produce a stronger case, it produces three sets of unknowns plus an untested interaction between them.

Research in humans

No published human study of the mixture, for any indication, of any design. Component by component the picture is barely better: BPC-157 has no published randomised controlled human trial; the TB-500 heptapeptide has not a single published human clinical trial and no human pharmacokinetics; injected GHK-Cu has no published human study either, the human data on GHK-Cu being exclusively topical cosmetic work in groups of 41 to 71 women over 8 to 12 weeks. So the three components contribute zero randomised human trials between them, and the blend adds none.

Animal and lab research

No animal study of the mixture could be located. There are separate rodent literatures for BPC-157 and for full thymosin beta-4, and preclinical wound-healing work on GHK-Cu, but no published experiment has administered these three together in any species. Claims of synergy therefore rest on nothing that has been tested.

Caveats. Beyond the total absence of blend research, three specific limitations apply. First, the composition is not standardised: 'GLOW' from one vendor need not contain the same amounts, or even the same molecules, as 'GLOW' from another. Second, the material is unregulated, so identity, purity, sterility and endotoxin content are not guaranteed; some vendors list the full thymosin beta-4 protein under the name TB-500, which is a different molecule from the heptapeptide. Third, the fixed ratio makes the product uninterpretable in use, which is discussed under dosing.

What it is used for

  • Marketed for skin quality, fine lines and general 'glow' — hence the name
  • Marketed for wound healing, scar appearance and post-procedure recovery
  • Marketed for soft-tissue and tendon recovery
  • None of these uses has been tested for the mixture. Each is an extrapolation from separate component claims, and those claims live in the individual components' own literature: BPC-157 has been reviewed systematically for orthopaedic use, where the evidence is preclinical 3; GHK-Cu has its own gene-expression literature 4; and full-length thymosin beta-4, which is not what is in this vial, has been trialled as an ophthalmic solution 5. There is no published study of the three together 2

Dosing

Dose
User protocols describe volumes rather than milligrams: typically 0.05-0.15 ml of reconstituted blend per injection. What that volume contains depends entirely on how much water went into the vial. Reconstituted as in the example below (a 50/10/10 mg vial in 3 ml), 0.05-0.15 ml corresponds to roughly 0.8-2.5 mg GHK-Cu with 0.17-0.5 mg each of BPC-157 and TB-500; the same volume from a 2 ml reconstitution carries half again as much
Frequency
once daily, in most circulating protocols five days per week
Route
subcutaneous
Duration
cycles of 4-8 weeks are described, followed by a break
  • There is no established dose. Every figure above comes from vendor pages and user protocols; not one of them derives from a clinical study of this mixture or of any of its components 23.
  • The dose has to be expressed as a volume, because a single vial delivers three compounds at once in whatever ratio the seller chose. There is no meaningful 'mg per dose' for a product like this.
  • The fixed ratio is the central practical problem. You cannot titrate one component: raising the BPC-157 dose necessarily raises the copper load fivefold as well. If you react badly, you cannot tell which of the three caused it, and there is no way to test that other than buying the components separately. And stopping means stopping all three at once.
  • The GHK-Cu content deserves separate attention. At 50 mg per vial this blend delivers copper, and daily injection over weeks represents a copper load that is not monitored in practice. Copper accumulation is a real toxicological endpoint, unlike most of the effects claimed for this product.
  • Anyone who genuinely wants these three compounds gains nothing from the blend and loses the ability to adjust or withdraw them individually.

These figures describe what the literature and published protocols report. They are not advice and not a dosing instruction.

Protocols

Daily injection course

user protocol — not validated

Source: Vendor pages and user protocols, stated as a volume of reconstituted blend

This is not a validated schedule. It is a pattern that circulates among users and sellers, reproduced because it is what people actually follow — not because it has been tested. No trial established these doses, this interval or this duration, and nobody is checking what is in the vial. Treat every number below as an assertion, not a finding.

Weeks 1-4 to 80.05-0.15 ml of reconstituted blend per injection, once daily, five days per week, subcutaneously
After the coursea break before repeating

The dose is a volume because one injection delivers three compounds at whatever ratio the seller chose; there is no meaningful milligram figure for the product as a whole. Since GHK-Cu is by far the largest fraction by mass, this schedule is also a daily copper load sustained for weeks, and nothing in it monitors that.

Schedules are reproduced as their source states them. Units, IU and milligrams explains why the figures are not interchangeable between products.

Reconstitution

Vial sizes
50/10/10 mg
Solvent
bacteriostatic water (0.9% benzyl alcohol)
Storage
Reconstituted at 2-8 °C, protected from light; the customary three to four weeks is a convention carried over from single peptides, not a stability finding for this mixture. Powder frozen and dark.

Worked example

A 70 mg vial (50 mg GHK-Cu + 10 mg BPC-157 + 10 mg TB-500) with 3 ml bacteriostatic water gives roughly 16.7 mg/ml GHK-Cu and 3.3 mg/ml each of BPC-157 and TB-500. 0.1 ml, that is 10 units on a U100 insulin syringe, then contains approximately 1.67 mg GHK-Cu, 0.33 mg BPC-157 and 0.33 mg TB-500. The three figures move together and cannot be changed independently.

The solution turns blue from the copper complex. Do not shake; let the water run down the wall of the vial. No published stability data exist for these three peptides in a shared copper-containing solution, so the usual shelf-life advice is an assumption here rather than an extrapolation.

Safety

Side effects

  • Injection site reactions: pain, redness, swelling, and with the copper complex sometimes a temporary blue-grey discoloration
  • Reported anecdotally for BPC-157: anxiety, itching, fatigue, nausea, headache, dizziness
  • Reported anecdotally for TB-500: fatigue, light-headedness, flu-like feeling
  • Copper-related effects from the GHK-Cu fraction: nausea and a metallic taste are reported; sustained excess copper intake is a recognised toxicological concern, although it has not been quantified for this route
  • Immunogenicity, named by the FDA as a risk for both BPC-157 and the LKKTETQ fragment when it placed them in category 2 of the interim 503A bulks list 1
  • No controlled human safety dataset exists for this mixture or for any of its three components administered by injection 23. The short list above reflects the absence of research, not a favourable safety profile.
  • Because the components arrive together, an adverse reaction cannot be attributed to any one of them

Do not use if

  • Active or previous malignancy. This is the most substantial concern and it applies to two components at once: BPC-157's angiogenic mechanism 23, and raised thymosin beta-4 expression which has been associated with cell migration, invasiveness and metastasis in several tumour types. Combining two pro-angiogenic agents in an oncological context is unwise on any reading of the evidence 2.
  • Wilson's disease or any condition of impaired copper handling, and concurrent copper supplementation: the GHK-Cu fraction is the largest component of the vial by mass, and GHK's biology is copper-dependent 4
  • Pregnancy and breastfeeding: no data for any component, let alone the mixture
  • Children and adolescents: no data
  • Competitive athletes under the WADA code: the blend contains substances on the prohibited list and no therapeutic use exemption is available for compounds that are approved nowhere
  • Anyone who needs to be able to identify the cause of a reaction — a fixed-ratio mixture makes this impossible by construction

Interactions

Not systematically studied, and interaction between the three components themselves has never been examined 2. Theoretically conceivable: additive angiogenic effects between BPC-157 and TB-500 3; interference by the copper fraction with zinc status on prolonged use 4; interactions between the BPC-157 fraction and agents acting on the nitric oxide system such as nitrates, PDE5 inhibitors and antihypertensives 3. All of this is reasoning from mechanism, not established fact.

Sources